# COMPREHENSIVE PEPTIDE INFORMATION TEMPLATE

## üìã **TEMPLATE STRUCTURE FOR EACH PEPTIDE**

Use this template to extract ALL information from each peptide folder. Follow this exact structure for consistency.

---

## üß¨ **BASIC INFORMATION**

### **Peptide Name**
- **Primary Name:** [e.g., BPC-157]
- **Alternative Names:** [e.g., Body Protection Compound 157, PL 14736]
- **Scientific Name:** [e.g., Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val]

### **Chemical Structure**
- **Full Chemical Name:** [Complete IUPAC name]
- **Amino Acid Sequence:** [e.g., Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val]
- **Molecular Weight:** [e.g., 1,419.6 Da]
- **Peptide Length:** [e.g., 15 amino acids (pentadecapeptide)]
- **Structural Modifications:** [Any modifications like D-amino acids, cyclization, etc.]

### **Classification**
- **Category:** [e.g., Tissue Repair Peptide, GLP-1 Agonist, Growth Hormone Secretagogue]
- **Origin:** [e.g., Synthetic, Derived from human gastric juice, Natural analog]
- **Research Status:** [e.g., Preclinical, Phase 1, Phase 2, Phase 3, FDA Approved]

---

## üìä **DOSING INFORMATION**

### **Standard Dosing Protocols**
- **Low Dose:** [e.g., 200-400 mcg per day]
- **Standard Dose:** [e.g., 400-600 mcg per day]
- **High Dose:** [e.g., 600-800 mcg per day]
- **Maximum Dose Studied:** [e.g., 10 mcg/kg/day in rats]

### **Administration Methods**
- **Primary Route:** [e.g., Subcutaneous injection]
- **Alternative Routes:** [e.g., Oral, Intramuscular, Intraperitoneal]
- **Reconstitution:** [e.g., 1 mg/mL in sterile saline]
- **Storage:** [e.g., -20¬∞C, avoid freeze-thaw cycles]

### **Treatment Duration**
- **Acute Treatment:** [e.g., 2-4 weeks]
- **Chronic Treatment:** [e.g., 4-8 weeks]
- **Maintenance:** [e.g., As needed basis]
- **Maximum Duration Studied:** [e.g., 14+ days in animals]

### **Dose Escalation (if applicable)**
- **Week 1-4:** [Dose]
- **Week 5-8:** [Dose]
- **Week 9-12:** [Dose]
- **Week 13-16:** [Dose]
- **Maintenance:** [Dose]

---

## üî¨ **MECHANISM OF ACTION**

### **Primary Targets**
- **Receptors:** [e.g., GLP-1R, GHRH-R, MC1R]
- **Pathways:** [e.g., cAMP, VEGF, EGF, NO synthesis]
- **Enzymes:** [e.g., DPP-4, ACE]

### **Biochemical Effects**
- **Upregulation:** [e.g., Growth factors, Insulin secretion]
- **Downregulation:** [e.g., Inflammation, Glucagon]
- **Modulation:** [e.g., Anti-inflammatory cytokines]

### **Cellular Effects**
- **Cell Types Affected:** [e.g., Fibroblasts, Endothelial cells, Œ≤-cells]
- **Cellular Processes:** [e.g., Migration, Proliferation, Differentiation]

---

## üéØ **THERAPEUTIC BENEFITS**

### **Primary Benefits**
1. [Benefit 1 with specific data]
2. [Benefit 2 with specific data]
3. [Benefit 3 with specific data]

### **Secondary Benefits**
1. [Benefit 1]
2. [Benefit 2]
3. [Benefit 3]

### **Clinical Efficacy Data**
- **Animal Studies:** [Specific results with references]
- **Human Studies:** [Specific results with references]
- **Success Rates:** [e.g., 50% faster healing, 14.9-16% weight loss]

---

## ‚ö†Ô∏è **SAFETY & SIDE EFFECTS**

### **Common Side Effects**
- **Gastrointestinal:** [e.g., Nausea (15-44%), Vomiting (5-24%)]
- **Injection Site:** [e.g., Redness, Swelling, Irritation]
- **Systemic:** [e.g., Headache, Fatigue]

### **Serious Side Effects**
- **Rare Events:** [e.g., Pancreatitis <1%]
- **Contraindications:** [e.g., Pregnancy, Thyroid cancer history]

### **Toxicity Data**
- **LD50:** [If available]
- **Maximum Safe Dose:** [e.g., 10 mg/kg/day in rodents]
- **Long-term Safety:** [Available data]

---

## üß™ **RESEARCH DATA**

### **Preclinical Studies**
- **Animal Models:** [e.g., Rats, Mice, Rabbits, Dogs]
- **Cell Cultures:** [e.g., Fibroblasts, Endothelial cells]
- **Key Findings:** [Specific results with references]

### **Clinical Trials**
- **Phase 1:** [Status and results]
- **Phase 2:** [Status and results]
- **Phase 3:** [Status and results]
- **FDA Status:** [Approved, Pending, Not submitted]

### **Key Research References**
- **Primary Studies:** [Author, Year, Journal]
- **Meta-analyses:** [If available]
- **Review Papers:** [Comprehensive reviews]

---

## üìà **PHARMACOKINETICS**

### **Absorption**
- **Bioavailability:** [e.g., 14-19% IM in rats, 45-51% in dogs]
- **Route Comparison:** [Oral vs. Injectable]

### **Distribution**
- **Half-life:** [e.g., <30 minutes]
- **Protein Binding:** [e.g., Albumin binding]
- **Volume of Distribution:** [If available]

### **Metabolism & Excretion**
- **Metabolism:** [e.g., DPP-4 degradation]
- **Clearance:** [If available]
- **Elimination:** [Route and time]

---

## üîç **SPECIFIC APPLICATIONS**

### **Primary Indications**
1. [Indication 1 with evidence level]
2. [Indication 2 with evidence level]
3. [Indication 3 with evidence level]

### **Emerging Applications**
1. [New research areas]
2. [Potential future uses]
3. [Combination therapies]

### **Contraindications**
- **Absolute:** [e.g., Pregnancy, Known allergies]
- **Relative:** [e.g., Renal impairment, Severe GI disease]

---

## üí∞ **PRICING & AVAILABILITY**

### **Cost Information**
- **Price Range:** [e.g., $299.99 per vial]
- **Dosage Cost:** [Cost per treatment cycle]
- **Availability:** [Available, Limited, Out of Stock]

### **Quality Considerations**
- **Purity Standards:** [e.g., >98% pure]
- **Storage Requirements:** [Specific conditions]
- **Shelf Life:** [Duration and conditions]

---

## üìö **EDUCATIONAL CONTENT**

### **Patient Information**
- **What it is:** [Simple explanation]
- **How it works:** [Layman's terms]
- **What to expect:** [Realistic expectations]

### **Professional Information**
- **Mechanism details:** [Scientific explanation]
- **Clinical protocols:** [Professional guidelines]
- **Research gaps:** [Areas needing study]

---

## ‚öñÔ∏è **LEGAL & REGULATORY**

### **Regulatory Status**
- **FDA Approval:** [Status and indications]
- **International Status:** [EMA, other agencies]
- **Research Use:** [IRB/IACUC requirements]

### **Legal Considerations**
- **Prescription Required:** [Yes/No]
- **Research Only:** [Current status]
- **Import/Export:** [Restrictions]

---

## üìù **TEMPLATE USAGE INSTRUCTIONS**

### **For Each Peptide Folder:**

1. **Extract from HTML file:**
   - Search for "FULL CHEMICAL NAME" section
   - Extract all technical information
   - Note all research references

2. **Extract from dosing files:**
   - Look for `.md` or `.txt` dosing files
   - Extract complete dosing protocols
   - Note safety information

3. **Extract from images:**
   - Note any gradient or product images
   - Document visual information

4. **Cross-reference with public folder:**
   - Check if peptide image exists in `/public`
   - Note any additional files

### **Data Quality Standards:**
- ‚úÖ Include ALL available information
- ‚úÖ Use exact quotes from research
- ‚úÖ Include specific numbers and percentages
- ‚úÖ Reference all studies mentioned
- ‚úÖ Note limitations and gaps in data
- ‚úÖ Include both technical and lay explanations

### **Formatting Requirements:**
- Use consistent structure across all peptides
- Include all sections even if data is limited
- Mark missing data as "Not available" or "Limited data"
- Use proper scientific notation
- Include units for all measurements

---

## üéØ **EXAMPLE COMPLETED TEMPLATE: BPC-157**

[This would be filled with all the extracted BPC-157 data following the above structure]

---

**Use this template for each peptide to ensure comprehensive, consistent, and professional information extraction!** 